Nanoparticles to Sequester and Facilitate In Vivo Excretion of Lipophilic Molecules

Award Information
Agency:
Department of Defense
Branch
Air Force
Amount:
$99,993.00
Award Year:
2011
Program:
STTR
Phase:
Phase I
Contract:
FA9550-11-C-0083
Award Id:
n/a
Agency Tracking Number:
F10B-T24-0132
Solicitation Year:
2010
Solicitation Topic Code:
AF10-BT24
Solicitation Number:
2010.B
Small Business Information
ADA Technologies, Inc. (Currently ADA TECHNOLOGIES INC.)
8100 Shaffer Parkway, Suite #130, Littleton, CO, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
148034408
Principal Investigator:
Steve Arzberger
Program Manager
(303) 792-5615
stevea@adatech.com
Business Contact:
Clifton Brown, Jr.
President&CEO
(303) 792-5615
cliffb@adatech.com
Research Institution:
University of Nevada
Kenneth H Sc.D.
Microbiology&Immunology
199 / School of Medicine
Reno, NV, 89557-0046
(775) 327-5255
Nonprofit college or university
Abstract
ABSTRACT: Mycotoxins are lipophilic agents derived from fungus that pose a significant public health problem around the world. The effects of mycotoxins include loss of human and animal life, increased healthcare and veterinary costs, reduced livestock production, and disposal of contaminated foods and feeds. Mycotoxins, such as aflatoxin and T-2 mycotoxins, have been reported to be weaponized as terrorism agents, suggesting the possibility of future deployment against military personnel is a real and present danger. Unfortunately, no effective treatment for mycotoxin exposure in either the acute or chronic setting currently exists. As a result, the United States Air Force has identified the need to fabricate a nanoparticle therapeutic that can sequester and then facilitate the excretion of mycotoxins. To address this need, ADA Technologies Inc. (ADA; Littleton, CO) and Professor Kenneth W. Hunter (University of Nevada at Reno) propose the development of nanoparticles with surface-bound biomolecules for the intravenous binding of lipophilic molecules, sequestration, and excretion from the human body BENEFIT: The proposed program will result in a nanoparticle therapeutic with the demonstrated ability of tightly binding and sequestering lipophilic molecules in solution. The result of the proposed program is anticipated to be the first commercial therapeutic for exposure to fungal toxins. Additional commercial applications may include diagnostics, sensors, and tools for the identification of various harmful molds.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government